HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

ACTRIMS 2017 Forum: MS Treatment Clinical Trials

Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.

Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.

slideshow image

ACTRIMS 2017 Forum: MS Treatment Clinical Trials

slideshow image

Clinical Follow-up of 411 Patients with Multiple Sclerosis Ten Years after Mitoxantrone Treatment Abstract link.

slideshow image

What is the sustained effect of mitoxantrone in patients with relapsing or progressive MS?

slideshow image

Mitoxantrone offered patients a sustained (albeit reduced at 5 years) effect at 10 years; treatment was more likely to benefit less active and disabled relapsing patients.

slideshow image

NEDA Analysis by Epoch in Patients with Relapsing Multiple Sclerosis Treated with Ocrelizumab: Results from the OPERA I and OPERA II Phase III Studies Abstract link.

slideshow image

How many patients with relapsing MS had no evidence of disease activity (NEDA) on ocrelizumab vs interferon beta 1-a (IFN β-1a)?

slideshow image

Patients on ocrelizumab were much more likely to achieve NEDA than patients on IFN β-1a.

slideshow image

Evaluation of No Evidence of Progression (NEP) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial Abstract link.

slideshow image

What proportion of patients with PPMS achieved no evidence of progression (NEP) on ocrelizumab?

slideshow image

Compared to placebo, ocrelizumab resulted in an increased proportion (47%) of patients with NEP at 120 weeks compared with placebo.

PreviousNext